$PHR Balance Sheet | Understand Stock

$PHR

$12.50 -$0.11 (0.87%) Live

$PHR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2027 As of Jul 31, 2026	Q1 FY2027 As of Apr 30, 2026	Q4 FY2026 As of Jan 31, 2026	Q3 FY2026 As of Oct 31, 2025	Q2 FY2026 As of Jul 31, 2025	Q1 FY2026 As of Apr 30, 2025	Q4 FY2025 As of Jan 31, 2025	Q3 FY2025 As of Oct 31, 2024	Q2 FY2025 As of Jul 31, 2024	Q1 FY2025 As of Apr 30, 2024	Q4 FY2024 As of Jan 31, 2024	Q3 FY2024 As of Oct 31, 2023	Q2 FY2024 As of Jul 31, 2023	Q1 FY2024 As of Apr 30, 2023	Q4 FY2023 As of Jan 31, 2023	Q3 FY2023 As of Oct 31, 2022	Q2 FY2023 As of Jul 31, 2022	Q1 FY2023 As of Apr 30, 2022	Q4 FY2022 As of Jan 31, 2022	Q3 FY2022 As of Oct 31, 2021
Assets
Current:
Cash, cash equivalents and restricted cash (including restricted cash of $— and $1,691 as of July 31, 2026 and January 31, 2026, respectively)
Settlement assets
Accounts receivable, net of allowance for doubtful accounts of $879 and $1,523 as of July 31, 2026 and January 31, 2026, respectively
Cardholder receivables
Deferred purchase price receivables
Accrued interest and fees receivables
Deferred contract acquisition costs
Prepaid expenses and other current assets
Total current assets
Property and equipment, net of accumulated depreciation and amortization of $90,281 and $94,193 as of July 31, 2026 and January 31, 2026, respectively
Capitalized internal-use software, net of accumulated amortization of $73,362 and $69,390 as of April 30, 2026 and January 31, 2026, respectively
Capitalized internal-use software, net of accumulated amortization of $77,389 and $69,390 as of July 31, 2026 and January 31, 2026, respectively
Operating lease right-of-use assets
Deferred contract acquisition costs
Intangible assets, net of accumulated amortization of $18,728 and $13,489 as of July 31, 2026 and January 31, 2026, respectively
Goodwill
Deferred tax assets
Other assets (includes $1,691 and $— of long-term restricted cash as of July 31, 2026 and January 31, 2026, respectively)
Long-term cardholder receivables
Long-term deferred purchase price receivables
Total Assets
Liabilities and Stockholders’ Equity
Current:
Settlement obligations
Current portion of debt and finance lease liabilities
Current portion of operating lease liabilities
Accounts payable
Accrued expenses
Due to healthcare providers
Deferred revenue
Other current liabilities
Total current liabilities
Long-term debt and finance lease liabilities
Operating lease liabilities, non-current
Long-term due to healthcare providers
Long-term deferred revenue
Long-term deferred tax liabilities
Other long-term liabilities
Total Liabilities
Stockholders’ Equity:
Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both July 31, 2026 and January 31, 2026; no shares issued or outstanding as of both July 31, 2026 and January 31, 2026
Common stock, $0.01 par value—500,000,000 shares authorized as of both July 31, 2026 and January 31, 2026; 63,516,793 and 62,020,186 shares issued as of July 31, 2026 and January 31, 2026, respectively
Additional paid-in capital
Accumulated deficit
Treasury stock, at cost, 971,236 and 301,003 shares as of January 31, 2023 and 2022, respectively
Accumulated other comprehensive loss
Treasury stock, at cost, 1,476,215 and 1,355,169 shares as of July 31, 2026 and January 31, 2026, respectively
Total Stockholders’ Equity

Total Liabilities and Stockholders’ Equity

Comments